Addressing species specific metabolism and solubility issues in a quinoline series of oral PDE4 inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 1, 2010, Pages 137-140

  Lunniss, C ^a   Eldred, C ^a   Aston, N ^a   Craven, A ^a   Gohil, K ^a   Judkins, B ^a   Keeling, S ^a   Ranshaw, L ^a   Robinson, E ^a   Shipley, T ^a   Trivedi, N ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Cinnoline; COPD; Cynomolgus monkey; PDE4; PK; Quinoline

Indexed keywords

CINNOLINE; PHOSPHODIESTERASE IV INHIBITOR; QUINOLINE; QUINOLINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; DRUG SELECTIVITY; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG SYNTHESIS; MONKEY; NONHUMAN; STRUCTURE ACTIVITY RELATION;

ADMINISTRATION, ORAL; ANIMALS; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 4; HETEROCYCLIC COMPOUNDS, 2-RING; MACACA FASCICULARIS; QUINOLINES; RATS; SOLUBILITY; STRUCTURE-ACTIVITY RELATIONSHIP;

MACACA FASCICULARIS;

EID: 72049122385     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.11.010     Document Type: Article

References (13)

1. Houslay M.D., Schafer P., and Zhang K.Y.J. Drug Discovery Today 10 (2005) 1503
2. Francisco J.S., and Hanania N.A. Curr. Opin. Pulm. Med. 11 (2005) 129
3. Hamblin J.N., Angell T.D.R., Ballantine S.P., Cook C.M., Cooper A.W.J., Dawson J., Delves C.J., Jones P.S., Lindvall M., Lucas F.S., Mitchell C.J., Neu M.Y., Ranshaw L.E., Solanke Y.E., Somers D.O., and Wiseman J.O. Bioorg. Med. Chem. Lett. 14 (2008) 4237
4. Lunniss C.J., Cooper A.W.J., Eldred C.D., Kranz M., Lindvall M., Lucas F.S., Neu M., Preston A.G.S., Ranshaw L.E., Redgrave A.J., Robinson J.E., Shipley T.J., Solanke Y.E., Somers D.O., and Wiseman J.O. Bioorg. Med. Chem. Lett. 19 (2009) 1380
5. Fura A. Drug Discovery Today 11 (2006) 133
6. Dickens M.J., Gilday J.P., Mowlem T.J., and Widdowson D.A. Tetrahedron 47 (1991) 8621
7. Dowlatshahi H.A. Synth. Commun. 1512 (1985) 1095
8. Baskin J.M., and Wang Z. Org. Lett. 4 (2002) 4423
9. Zhu W., and Ma D. J. Org. Chem. 70 (2005) 2696
10. Frank J., and Katritzky A. J. Chem. Soc., Perkin Trans. 2 (1976) 1428
11. Warshel A., and Papazyan A. Curr. Opin. Struct. Biol. 8 (1998) 211
12. Inhibition of LPS induced TNF-α production in human whole blood was carried out using MSD technology as described in WO2007036733.
13. The ability of compounds to inhibit catalytic activity at PDE4B was determined by Scintillation Proximity Assay (SPA) as described in patent WO2004103998.